Evaluation of an automated genome interpretation model for rare disease routinely used in a clinical genetic laboratory
Genetics in Medicine · 2023-06 · 25 (6) · 100830
DOI: 10.1016/j.gim.2023.100830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine, 2023-06. Verfasst von Linyan Meng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Baylor Genetics, Houston, TX. Hauptthemen laut MEDLINE: Rare Diseases, Laboratories, Clinical. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The analysis of exome and genome sequencing data for the diagnosis of rare diseases is challenging and time-consuming. In this study, we evaluated an artificial intelligence model, based on machine learning for automating variant prioritization for diagnosing rare genetic diseases in the Baylor Genetics clinical laboratory. METHODS: The automated analysis model was developed using a supervised learning approach based on thousands of manually curated variants. The model was evaluated on 2 cohorts. The model accuracy was determined using a retrospective cohort comprising 180 randomly selected exome cases (57 singletons, 123 trios); all of which were previously diagnosed and solved through manual interpretation. Diagnostic yield with the modified workflow was estimated using a prospective "production" cohort of 334 consecutive clinical cases. RESULTS: The model accurately pinpointed all manually reported variants as candidates. The reported variants were ranked in top 10 candidate variants in 98.4% (121/123) of trio cases, in 93.0% (53/57) of single proband cases, and 96.7% (174/180) of all cases. The accuracy of the model was reduced in some cases because of incomplete variant calling (eg, copy number variants) or incomplete phenotypic description. CONCLUSION: The automated model for case analysis assists clinical genetic laboratories in prioritizing candidate variants effectively. The use of such technology may facilitate the interpretation of genomic data for a large number of patients in the era of precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Baylor Genetics, Houston, TX.
- Genomic Research Department, Emedgene, an Illumina Company, Tel Aviv, Israel.
- Genomic Research Department, Emedgene, an Illumina Company, Tel Aviv, Israel; Institute of Research in Military Medicine, The Faculty of Medicine, The Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem,…
- Baylor Genetics, Houston, TX.
- Genomic Research Department, Emedgene, an Illumina Company, Tel Aviv, Israel. Electronic address: stzur@illumina.com.
Zitieren
APA
Meng, L., Attali, R., Talmy, T., Regev, Y., Mizrahi, N., Smirin-Yosef, P., Vossaert, L., Taborda, C., Santana, M., Machol, I., Xiao, R., Dai, H., Eng, C., Xia, F., & Tzur, S. (2023). Evaluation of an automated genome interpretation model for rare disease routinely used in a clinical genetic laboratory. Genetics in Medicine, 25(6), 100830. https://doi.org/10.1016/j.gim.2023.100830
Vancouver
Meng L, Attali R, Talmy T, Regev Y, Mizrahi N, Smirin-Yosef P, et al. Evaluation of an automated genome interpretation model for rare disease routinely used in a clinical genetic laboratory. Genetics in Medicine. 2023;25(6):100830. doi:10.1016/j.gim.2023.100830
BibTeX
@article{Meng2023,
author = {Meng, Linyan and Attali, Ruben and Talmy, Tomer and Regev, Yakir and Mizrahi, Niv and Smirin-Yosef, Pola and Vossaert, Liesbeth and Taborda, Christian and Santana, Michael and Machol, Ido and Xiao, Rui and Dai, Hongzheng and Eng, Christine and Xia, Fan and Tzur, Shay},
title = {Evaluation of an automated genome interpretation model for rare disease routinely used in a clinical genetic laboratory},
journal = {Genetics in Medicine},
year = {2023},
volume = {25},
number = {6},
pages = {100830},
doi = {10.1016/j.gim.2023.100830}
}
EUVIMED